Welcome to our dedicated page for Amarin news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin stock.
Amarin Corporation plc develops and commercializes cardiovascular therapeutics centered on icosapent ethyl, marketed as VASCEPA in the United States and VAZKEPA in Europe. Company news commonly covers product revenue, cash flow, U.S. prescription trends, partner-led international commercialization, and European distribution under an exclusive licensing and supply agreement with Recordati.
Updates also include medical-society guideline discussions, REDUCE-IT analyses, peer-reviewed publications, and scientific meeting presentations on cardiovascular risk reduction, elevated triglycerides, eicosapentaenoic acid, and lipoprotein(a) oxidation.
Amarin Corporation plc (NASDAQ:AMRN) announced Tom Reilly as the new Chief Financial Officer, effective June 20, 2022, following Michael W. Kalb's resignation to pursue other interests. Reilly, with over 20 years of experience in global financial leadership, previously served as CFO for Cara Therapeutics and held senior positions at Allergan and Novartis. This leadership change aims to enhance Amarin's financial management as the company expands internationally. CEO Karim Mikhail expressed confidence in Reilly's ability to support Amarin's vision to combat cardiovascular disease.
Amarin Corporation plc (NASDAQ:AMRN) announced significant Board of Directors changes, effective May 19, 2022. Erin Enright and Alfonso "Chito" Zulueta have been appointed as new board members, bringing extensive expertise in healthcare and global marketing. Per Wold-Olsen has been elevated to Chairman of the Board. Retirements of long-serving board members David Stack and Joe Zakrzewski are planned for after the upcoming Annual Meeting. These actions aim to enhance the Board’s capabilities to support Amarin’s strategic growth initiatives, reinforcing a commitment to sustainable development.
Amarin Corporation (NASDAQ:AMRN) presented important research on VASCEPA® (icosapent ethyl) at the American Heart Association’s Quality of Care and Outcomes Research sessions. The studies indicate that treating 3.6 million eligible patients could prevent up to 97,000 cardiovascular events annually, potentially saving $3.4 billion in associated costs. Cost-effectiveness analyses show that VASCEPA offers better outcomes at a daily cost of $4.16, affirming its role in cardiovascular disease management. The company emphasizes that VASCEPA can significantly reduce healthcare costs linked to cardiovascular disease.
Amarin Corporation plc (NASDAQ:AMRN) announced that its CEO, Karim Mikhail, will present at two upcoming investor conferences. The H.C. Wainwright Global Investment Conference will be held from May 23-26, 2022, with Mikhail's presentation scheduled for May 25 at 12:00 p.m. ET. The Jefferies Healthcare Conference is set for June 8-10, 2022, where he will present on June 8 at 1:00 p.m. ET. Both events will be webcast live and available for later viewing on the company’s investor relations website, emphasizing Amarin's commitment to cardiovascular disease management and investor communication.
Amarin Corporation announced its financial results for Q1 2022, reporting total net revenue of $94.6 million, a 33% decline year-over-year. The U.S. market faced challenges from three generic entrants, resulting in a 34% decrease in net product revenue. However, the company made progress in its European expansion strategy, securing national reimbursement for VAZKEPA in Sweden and initiating reimbursement discussions in several European markets. Despite the revenue drop, Amarin aims to maximize VASCEPA's value and is committed to operational excellence.
The latest REDUCE-IT study analysis published in JACC highlights the significant cardiovascular benefits of VASCEPA (icosapent ethyl) for patients with a history of myocardial infarction (MI). The study found a 35% reduction in total ischemic events, including 34% in non-fatal MI and 30% in cardiovascular deaths. Conducted on 3,693 patients, this sub-analysis reinforces icosapent ethyl as an essential treatment for mitigating severe cardiovascular risks in high-risk patients. The safety profile showed consistent results, with some increased risks of atrial fibrillation and minor bleeding.
Amarin Corporation (NASDAQ:AMRN) announced that its partner HLS Therapeutics has finalized negotiations with Canada's pan-Canadian Pharmaceutical Alliance for the public reimbursement of VASCEPA® (icosapent ethyl). A Letter of Intent was signed, allowing HLS to pursue coverage across Canadian provinces. This milestone aims to enhance access for statin-treated patients with cardiovascular disease and elevated triglycerides. The exclusive commercialization agreement includes payments up to $65 million to Amarin, along with tiered royalties on VASCEPA sales in Canada.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on May 4, 2022, at 8:00 a.m. ET, to discuss its first quarter 2022 financial results. This call follows the anticipated release of the financial results earlier that day. Investors can access the live call via the investor relations section of Amarin's website or by dialing in. The company is focused on advancing cardiovascular disease management and has a global presence with offices in multiple countries.
Amarin Corporation (NASDAQ: AMRN) announced significant findings from an in vitro trial presented at the ACC’s 71st Annual Scientific Session. The study revealed that combinations of Eicosapentaenoic Acid (EPA) with statins—atorvastatin and rosuvastatin—reduced lipid oxidation by 86% and 75%, respectively (p<0.001). These results enhance the understanding of EPA's role in combating cardiovascular risks when paired with statins, aligning with previous REDUCE-IT trial results. The trial emphasizes potential benefits for high-risk patients needing stronger solutions.
Amarin Corporation plc (NASDAQ:AMRN) achieved a significant milestone by securing its first national reimbursement for VAZKEPA in Sweden, marking an important phase in its international expansion strategy. The Swedish Dental and Pharmaceutical Benefits Agency approved VAZKEPA for statin-treated patients with established cardiovascular disease at a monthly cost of 1,640 SEK. The company aims to expand its presence in several other European countries and is actively pursuing regulatory approvals in markets like Australia, New Zealand, and Saudi Arabia. This decision is expected to unlock significant revenue potential for Amarin.